Prevention of Febrile Neutropenia
Author:
Klastersky Jean A.
Publisher
Springer Healthcare Ltd.
Reference34 articles.
1. Aapro MS, Bohlius J, Cameron DA, et al; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8-32.
2. Moreau M, Klastersky J, Schwartzbold A, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenian hematological malignancies. Ann Oncol. 2009;20:513-519.
3. Hansson EK, Friberg LE. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. Cancer Chemother Pharmacol. 2012;69:881-890.
4. Chen C, Chan A, Yap K. Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. J Oncol Pharm Pract. 2012;19:111-120.
5. Chang LL, Schneider SM, Chiang SC, Horng CF. Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer. Cancer Nurs. 2013;36:198-205.